Author

Y. Zakharia

h-index 35 View on Semantic Scholar

We have 3 of 351 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

11 Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)

Abstract Background Immune checkpoint inhibitor-based combinations represent the standard of care for advanced renal cell carcinoma (RCC). The OMNIVORE trial (NCT03652142) investigated a response-adaptive strategy including treatment discontinuation in early nivolumab responders (Arm A) and salvage ipilimumab addition...

M. Serzan, Wan-Ling Xie, B. McGregor et al. · The Oncologist · 0 citations

Open access Sep 2026

12 Farnesyl Transferase Inhibitor (FTI) Darlifarnib Combined with Cabozantinib in Renal Cell Carcinoma (RCC): Updated Phase 1a Results from FIT-001

Abstract Background VEGFR- and IO-targeted therapies for metastatic RCC have limitations that can lead to disease progression, highlighting the need for well-tolerated and effective combination strategies. VEGFR-TKI resistance occurs through multiple escape mechanisms, with the mTOR pathway playing a central role in su...

Adanma Ayanambakkam, Y. Zakharia, L. Rosen et al. · The Oncologist · 0 citations

Open access Jun 2026

Structured reasoning failures compromise LLM interpretation of clinical oncology notes.

Evaluating and monitoring reasoning fidelity should be a prerequisite for safe deployment of LLMs in oncology decision support, as endpoint accuracy alone may mask clinically meaningful reasoning failures.

Matthew Kenaston, U. Ayub, Mihir Parmar et al. · npj Digital Medicine · 0 citations